HENAN LINGRUI PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.45 CNY | +5.38% |
|
+6.17% | +48.74% |
| Sales 2024 * | 3.96B 547M 45.68B | Sales 2025 * | 4.52B 624M 52.07B | Capitalization | 13.62B 1.88B 157B |
|---|---|---|---|---|---|
| Net income 2024 * | 641M 88.54M 7.39B | Net income 2025 * | 746M 103M 8.6B | EV / Sales 2024 * | 3.44 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3.01 x |
| P/E ratio 2024 * |
21.4
x | P/E ratio 2025 * |
18.3
x | Employees | 2,524 |
| Yield 2024 * |
3.64% | Yield 2025 * |
4.27% | Free-Float | 74.14% |
More Fundamentals
* Assessed data
More news
| 1 day | +5.38% | ||
| 1 week | +6.17% | ||
| Current month | +18.65% | ||
| 1 month | +18.65% | ||
| 3 months | +43.06% | ||
| 6 months | +51.22% | ||
| Current year | +48.74% |
1 week
22.77
25.77
1 month
20.5325.77
Current year
16.1525.77
1 year
14.3025.77
3 years
9.2025.77
5 years
7.6625.77
10 years
5.8725.77
| Managers | Title | Age | Since |
|---|---|---|---|
Wei Xiong
CEO | Chief Executive Officer | 40 | - |
Peng Yu
DFI | Director of Finance/CFO | 55 | - |
Jia Shu Jiang
BRD | Director/Board Member | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wei Xiong
CEO | Chief Executive Officer | 40 | - |
Xi Zhen Wu
BRD | Director/Board Member | 60 | 18/06/18 |
Jun Yang
BRD | Director/Board Member | 55 | 18/23/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | +1.01% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 25.45 | +5.38% | 13 586 880 |
| 29/24/29 | 24.15 | -4.55% | 16,618,680 |
| 26/24/26 | 25.3 | +8.68% | 20,016,350 |
| 25/24/25 | 23.28 | +1.13% | 4,303,415 |
| 24/24/24 | 23.02 | -2.99% | 10,312,180 |
End-of-day quote Shanghai S.E., April 30, 2024
More quotes
Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.
Sector
Pharmaceuticals
Calendar
20/05/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
24.15
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +48.74% | 1.88B | |
| +39.33% | 6.01B | |
| -18.38% | 4.4B | |
| -9.17% | 3.17B | |
| +3.98% | 3.07B | |
| -3.41% | 2.51B | |
| -4.82% | 1.73B | |
| -1.24% | 1.65B | |
| -8.96% | 1.58B | |
| +39.87% | 1.4B |
- Stock Market
- Equities
- 600285 Stock
